Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097955 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
NCT00097955 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 496 participants.
The verdict
NCT00097955, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
Study Summary
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
Interventions
- DRUG aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097955
The ClinicalTrials.gov registry entry for NCT00097955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aliskiren is the first listed.
NCT00097955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097955 about?
NCT00097955 is a clinical study titled "Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria". Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
What is the current status of trial NCT00097955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2004-10. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00097955?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00097955?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.